Review Article

BIOCHEMICAL BASIS AND EMERGING MOLECULAR TARGETS TO TREAT DIABETIC RETINOPATHY

*KUMARI SUCHITRA[1], PANDA TARUN K[2]

AUTHOR DETAILS

[1]Asst. Professor, Dept. of Biochemistry, All India Institute of Medical Sciences (AIIMS), Bhubaneswar-19, Odisha.

[2]Asst. professor, Dept. of Ophthalmology, SCB Medical College and Hospital, Cuttack, Odisha.

ABSTRACT

Diabetes being considered as an epidemic, long term untreated complicated diabetes resulting in retinopathy will be a leading cause of blindness worldwide. Many cross-sectional studies reported a strong relationship between chronic hyperglycaemia and development, progression of retinopathy, however the underlying mechanism that cause retinal microvascular damage following prolonged hyperglycaemia, yet to be revealed. Continued research worldwide focuses on understanding the molecular basis with the ultimate goal to prevent diabetic retinopathy by developing newer therapeutic targets. This article reviews multiple biochemical pathways that are implicated in diabetic retinopathy. Recent advancement in the molecular basis of the disease as well as clinical trials undertaken to target these molecules in order to block the signalling cascade prevailing in diabetic retinopathy is also discussed. This review highlights the recent therapeutic targets to prevent the onset as well as the progress of retinopathy in diabetes.

KEYWORDS

Hyperglycaemia, microvascular damage, molecular basis, therapeutic targets, signalling cascade.

INTRODUCTION

Increased prevalence of Type-2 diabetes mellitus and insulin resistance (a pre diabetic condition) is a major health concern in India. As per International Diabetic Federation (IFD) estimates , the number of patients with diabetes is expected to be more than double by 2030.Diabetes has many underlying interrelated pathways that lead to potentially blinding complications like diabetic retinopathy.[1,2] Diabetic retinopathy is the most frequent microvascular complication of diabetes and is one of the major causes of vision loss worldwide. Review of population based studies revealed approximately 34.6% of diabetics have retinopathy.[3] Diabetic retinopathy occur both in type 1 and type 2 diabetes and is strictly related to poor glycaemic control over a prolonged duration of disease, however there are substantial differences between type 1 and type 2 diabetes in terms of clinical presentations and prevalence. Prevalence of retinopathy is more in type 1 than in type 2 diabetes and more in males than in female.[4] Intensive glucose control early in the course of the disease produced significant benefits on microvascular complications i.e. retinopathy both in type1 and type2 Diabetes mellitus.[5] In addition to the extent and duration of chronic hyperglycaemia , other biochemical mechanisms like Polyol accumulation, Protein Kinase C pathway, Oxidative damage, non-enzymatic protein glycosylation, increased hexosamine pathway flux as well as recently documented endothelium related dysfunction of the coagulant and anticoagulant pathway, cytokines, interleukins, Endothelin 1 also play a role in the pathogenesis of diabetic retinopathy. All these pathways ultimately lead to increased oxidative stress, inflammation, and vascular occlusion that cause upregulation of factors such as vascular endothelial growth factor (VEGF), insulin like growth factor (IGF), stromal derived factor-1 (SDF-1), angiopoietins (Ang-2), tumour necrosis factor (TNF), and basic fibroblast growth factor-2 (bFGF) leading to capillary damage, ischaemia with unregulated angiogenesis that is pathognomic of diabetic retinopathy.[6]

Genetic studies revealed involvement of a number of genes in diabetic retinopathy. Aldose reductase (ALR2),receptor for advanced glycation end products (RAGE) ,endothelial nitric oxide synthase (eNOS), vascular endothelial growth factor (VEGF), paraoxonase1(PON1), plasminogen activator inhibitor1 (PAI) are some of the important genes found to be associated with diabetic retinopathy. Polymorphisms at the regulatory regions of these genes have been evaluated as risk alleles for the progression of diabetic retinopathy.[7] According to the Diabetes Control and Complications Trial (DCCT) intensive treatment and improved glucose control delayed the onset of retinopathy and slowed down its progression in comparison to conventional treatment.[8] Laser

photocoagulation and Focal/grid photocoagulation have been effective in reducing further vision loss in diabetic retinopathy[9] ; however, these procedures are associated with potential complications.[10] To avoid these complications, new drugs and therapeutic targets must be identified which can disrupt the cascade of events underlying the pathogenesis of Diabetic retinopathy. So there is a need for better understanding of molecular basis of diabetic retinopathy in greater details so that newer therapeutic interventions can be developed for effective management.

Biochemical mechanisms of diabetic retinopathy:

Diabetes control and complications trial (DCCT) and United Kingdom Prospective Diabetes Study (UKPDS) group reported strong association between chronic hyperglycaemia and development and progression of diabetic retinopathy.[11,12] According to DCCT mean risk for development of any retinopathy was reduced by 76% in the intensive therapy compared to the conventional therapy. With established retinopathy the intensive group had a higher incidence of progression during the first year whereas from 3 years onwards, the progression of retinopathy was reduced in the intensive group by 54%.United Kingdom Prospective Diabetes Study (UKPDS) showed that patients who were assigned to intensive glucose control had less need for retinal photocoagulation .Both studies showed that glycaemic control is protective .Hyperglycaemia is involved in the pathogenesis of diabetic retinopathy (Figure 1), nephropathy, neuropathy and macro vascular disease via the following mechanisms i.e. increased flow through the aldose-reductase pathway ; non enzymatic glycation and glycoxidation with formation of advanced glycation end products (AGEs); increased de-novo synthesis of diacylglycerol from glucose, causing protein-kinase C (PKC) activation; oxidative-nitrosative stress with overproduction of reactive oxygen species (ROS).[13,14] Therefore beside the optimal glycaemic control , pharmacologic inhibition of these pathways might prevent loss of retinal pericytes, micro aneurysm formation, changes in retinal hemodynamics that ultimately result in neovascularization a characteristic feature in diabetic retinopathy.


Figure 1. Hyperglycaemia induced biochemical alterations in diabetic retinopathy

A) Increased glucose flux through polyol pathway:

Aldose Reductase (AR) present in the retina reduces glucose into sorbitol using nicotinamide adenine dinucleotide phosphate (NADPH) as a cofactor. Sorbitol dehydrogenase (SDH) with NAD+ as cofactor subsequently converts sorbitol into fructose. Since sorbitol is impermeable to cellular membranes, it accumulates within the cell and later metabolised to fructose. Built up of sorbitol (Figure 2) is an important cause of osmotic damage to retinal cells.[15] Fructose can be phosphorylated to fructose-3-phosphate that later can be degraded to 3-deoxyglucosone, both of which are strong glycating agents and result in the production of Advanced Glycated End Products i.e. AGEs.[16] Increased utilisation of NADPH as a cofactor in the polyol pathway results in less NADPH availability for use by glutathione reductase (enzyme involved in generation of reduced glutathione).Reduced glutathione being a free radical scavenger , its decreased level diminishes protective response against oxidative stress.[17] Exaggerated NADH oxidase activity due to increased cytosolic NADH/NAD+ ratio by SDH results in increased production of reactive oxygen species(ROS) within retinal cells.[18] Under euglycemic conditions, hexokinase enzyme has higher affinity for glucose hence the formation of sorbitol is very low . However, in hyperglycaemic state there is a substantial increase in intracellular sorbitol levels. Aldose reductase has a high capacity and a low affinity for glucose but sorbitol dehydrogenase (SDH) has a high affinity and a low capacity for sorbitol. So only during hyperglycaemic state Aldose reductase activity is increased and sorbitol oxidation is relatively independent of the sorbitol concentration within the physiological ranges.[19,20]

In diabetes, the sorbitol pathway activity is more in tissues like retina, kidney, peripheral nerves and blood vessels where insulin is not required for cellular glucose uptake. The polyol pathway seem to be an important mechanism for the ganglion cell apoptosis and Müller glial cell activation.[21,22] Aldose reductase is found in Ganglion and Müller cells of the retina. Since neuroglial changes may cause vascular changes the inhibition of the polyol pathway could also prevent the vascular abnormalities of diabetic retinopathy. Inhibition of aldose reductase was also able to prevent the early activation of complement in the retinal vessel wall as well as the apoptosis of vascular pericytes and endothelial cells and the development of acellularcapillaries.[23] Retinal endothelial cells showed aldose reductase immunoreactivity, and human retinas exposed to high glucose in organ culture increased the production of sorbitol.[24] Experimental evidences suggest that defects in the polyol pathway may produce thickening of the capillary basement membrane, loss of mural pericytes and micro aneurysm formation ,the vascular changes characteristics of diabetic microangiopathy. So polyol pathway has been an extremely attractive target for the treatment of diabetic retinopathy. Animal data showed that aldose reductase has an early role in the pathogenesis of diabetic retinopathy but studies of inhibition of polyol pathway in vivo have yielded inconsistent results .The Sorbinil trial also indicated that sorbinil did not prevent the worsening of the disease except for a slower progression rate.[25] Animal

models suggest that AR inhibitor fidarestat, is active in the treatment of diabetic retinopathy. Fidarestat (Figure 5) being an inhibitor of aldose reductase neutralizes diabetes-associated retinal oxidative stress and (ADP-ribose) polymerase formation.[26] This indicates the rationale for the development of aldose reductase inhibitors for counteraction of polyol pathway.[27] In the streptozotocin diabetic rats, fidarestat treatment decreased sorbitol and fructose concentrations in the retina. Similarly in the rat model with retinal ischemia reperfusion injury, fidarestat treatment caused increased AR expression and cell death with decreased sorbitol pathway intermediate accumulation.[28] Fidarestathas a role in ICAM-1 mRNA expression and leukocyte accumulation in the retina. Immunohistochemical study also revealed the suppressive effect of fidarestat on the expression of ICAM-1.[29] A double-blind study in patients with diabetic neuropathy documented the efficacy of sorbinil, an aldose reductase inhibitor, against morphological signs of degeneration associated with a decrease in the nerve sorbitol level.[30] Zenarestat , another aldose reductase inhibitor also reported same results.[31] Sorbinilretinopathy trial indicated that sorbinil had no clinically important effect on the course of human diabetic retinopathy.[25] However Zenerestat had a positive effect on diabetic neuropathy progression[32] thus creating a hope in the use of Aldose reductase inhibitors in diabetic retinopathy that needs further clinical trials.


Figure 2. Polyol Pathway and role of Aldose reductase Inhibitor

A) Non enzymatic Protein Glycosylation:

Chronic hyperglycaemia leads to accumulation of Advanced Glycation End Products (AGES) that play an important role in pathogenesis of retinopathy in diabetes.[33] AGEs are heterogeneous molecules formed by nonenzymatic reaction of free amino groups of proteins, lipids and nucleic acids with the reducing sugars . Schiff base is formed that undergoes spontaneously rearrangement (Maillard reaction) on itself to produce an Amadori adduct (Figure 3). Most glycated proteins are eliminated in physiological conditions, they accumulate in the presence of diabetes and undergo further glycation and molecular rearrangement that lead to the formation of AGEs.[34]

Some of the AGEs in human are Carboxymethyllysine (CML), Carboxyethyllysine (CEL) and Pentosidine out of which CML have been localized to retinal blood vessels of diabetes patients and significant correlation has been found between

CML and the degree of retinopathy pointing its role in Diabetic retinopathy.[35] AGEs are involved in microvascular and macrovascular complications through the formation of covalent crosslinks with molecules of the basement membrane of the extracellular matrix and the vessel wall components. Binding of AGEs with a variety of cell-surface AGE binding receptors(receptor for advanced glycation end products i.e. RAGEs) leads to cellular activation of prooxidant, proinfammatory events .Various signalling pathways (Figure 4) that are activated by AGE receptor binding include tyrosine phosphorylation of Janus kinase (JAK)/signal transducers and activators of transcription (STAT)[36], recruitment of phosphatidylinositol 3 kinase to Ras[37,] activation of protein kinase C[38] and oxidative stress by NFk Band AP-1 transcription[39] .CML interact with vascular endothelium via RAGE activating nuclear factor kappa B (NF-κ B), that increase expression of adhesion molecules and secretion of tumour necrosis factor alpha (TNFα) and VEGF.


Figure 3. Formation of Advanced Glycation End products

Recent investigations suggest that the AGE-RAGE interaction might increase VEGF gene transcription by NADPH oxidase-mediated ROS generation and nuclear factor- κ.B (NF-κ.B) activation via Ras mitogen activated protein kinase (MAPK) pathway.[40,41] Knocking down of integrin-linked kinase (ILK) gene expression with siRNA inhibited the expression of VEGF and intercellular adhesion molecule 1 (ICAM-1) that indicates the ILK response to high glucose and its role in pathogenesis of diabetic retinopathy (DR).[42,43]

Evidences from animals studies suggest that exposure to high levels of AGEs cause vascular and renal complications.[44,45,46] Diabetic rats when treated with Aminoguanidine hydrochloride (AGE inhibitor), accumulation of AGE was significantly reduced that prevented formation of micro aneurysms, acellular capillaries and pericyte loss.[47] Treatment with vitamin B6 derivatives, an AGE inhibitor also found to be protective against capillary drop out in diabetic rats.[44] Such observations suggest that AGE accumulation and its interaction with RAGE are interconnected mechanisms in Diabetic retinopathy and inhibition of these pathways could be an important therapeutic avenue.[48] Current treatments focus on preventing the AGE formation, breaking established crosslinks and reducing receptor-ligand interactions .Recently Park et al. reported that the Wnt pathway inhibitor that i.e. a Pigment Epithelium-Derived Factor (PEDF), a serine proteinase inhibitor overexpression could attenuate Wnt signaling induced by retinal ischemia.[49] PEDF is also found to inhibit NADPH oxidase mediated ROS generation and VEGF

expression thus preventing AGE induced oxidative stress and apoptosis in retinal pericytes.[50] Yamagishi et al documented that injection of AGEs to normal rats increases RAGE and ICAM-1 expression that could be prevented by treatment with PEDF by inhibiting superoxide generation and NFkB activation in endothelial cells.[51] Aminoguanidine, a potent inhibitor of AGE mediated cross-linking, has been shown to reduce diabetic vascular complications including retinopathy in experimental animals.[52]

B) Oxidative stress:

Imbalance between the level of ROS and the antioxidant defence mechanisms in a biological system leads to oxidative stress. Hyperglycemia induces overproduction of ROS and oxidative stress (Figure 4) reflected by increased Malondialdehyde, isoprostane, nitrotyrosine or 8-hydroxy-2 deoxyguanosine levels and decreased antioxidant status.[53,54] Reactive oxygen species are produced by glucose auto-oxidation, protein glycation, increased flux through the polyol pathway, and prostanoid production. ROS and reactive nitrogen species (RNS) act on lipids, protein and DNA molecules leading to cross-link formation, lipid peroxidation and protein modification. Pericytes are highly sensitive to the oxidative stress and increased rate of apoptosis due to decreased level of antioxidant enzymes.[55] Progressive Pericyte loss leads to pore formation in the blood vessel wall thus proteins are leaked , a characteristic finding in non proliferative diabetic retinopathy i.e. hard exudates.


Figure 4. Interrelationship of Biochemical Mechanisms in diabetic retinopathy

Animal studies documented that oxidative stress cause development of retinopathy in diabetes and it prevent retinopathy to reverse even after euglycemic state is achieved.[56] In diabetes the antioxidant enzymes i.e. SOD, glutathione reductase, glutathione peroxidase, catalase are found decreased in the retina.[57] It is also reported that type 2 diabetes mellitus is associated with reduced plasma total antioxidant status and increased plasma oxidisability with reduced plasma ascorbic acid and vitamin E.[58] Lipoicacid scavenge ROS and reduces glutathione to maintain a healthy cellular redox state.[59] Lipoic acid supplementation prevents

diabetes-induced increase in nitrotyrosine and activation of NF-κB , decrease VEGF and oxidatively modified proteins in the rat retina.[60] Vitamin E through non enzymatic mechanisms act as free radical scavenger in DR.[61] Trolox prevent the loss of pericytes in diabetic rats[62] Carotenoid, lutein and zeaxanthin prevented progression of DR and maintained normal retinal function, mitochondrial homeostasis and inflammatory mediators.[63]

C) Protein Kinase C pathway:

Protein kinase C (PKC) is a family of 10 enzymes, in which the β 1/2 isoforms are closely associated with the development of diabetic retinopathy.[64] So far 12 PKC isoforms have been isolated and can be divided into 3 groups i.e. classical, novel and typical. Classical isoform (PKC-α,β ½,δ) are enhanced by Diacylglycerol (DAG) and have been linked to vascular dysfunction and pathogenesis of DR.[65] Hyperglycaemia increase glucose flux through the glycolytic pathway, which increases DAG , the key activator of PKC.[66] activation of PKC has a cascade-like effect on several other pathways that influence endothelial permeability, retinal hemodynamic, and expression of vascular endothelial growth factor (VEGF) in the retinal along with leukocyte adhesion.[67,68] Upregulation of PKC contribute to the pathogenesis of diabetic retinopathy i.e. extracellular matrix (ECM) remodelling, differential synthesis of extra cellular matrix proteins, release of angiogenic factors, endothelial and leukocyte dysfunction leading to vascular changes pertaining to DR.[69]

PKC inhibitors are new potential therapeutics useful in DR. They can delay the onset or prevent the progression of vascular complications of diabetes. Isoquinoline sulphonamides and staurosporine the first and second generation PKC inhibitors are of therapeutic interest.[70,71,72,73] Ruboxistaurin mesylate was reported in science.[74] Vitamin E can inhibit PKC activity by decreasing DAG contents by activation of DAG kinase.[75,61] PKC β inhibitor Ruboxistaurin (Figure 5) reduces the mitogenic response to VEGF, in contrast with PKC-α inhibition.[76] Selective inhibition is very crucial to develop clinically safe therapeutic PKC inhibitors. Tuttle et al documented that PKC isoform selective inhibitors can be used for chronic clinical treatment with nominal side effects.[77] So, selective PKC inhibitors are likely new potential therapeutics in DR. Endothelium related dysfunction of the coagulant and anticoagulant pathway has been documented in diabetes.[78]

D) Miscellaneous Mechanisms:

- In case of proliferative diabetic retinopathy a hypercoagulable state is present due to conversion of the endothelium from a thermoresistant to a thermogenic surface with activation of extrinsic haemostatic pathway. Moreover finding of anti-pericyte and phospholipid binding autoantibodies (eg. Leupus anticoagulants) as well as presence of T lymphocytes, B lymphocytes , HLA DR/DQ expressing cells ,macrophages and Ig deposits in the vitreous and the pre retinal membrane suggest immunological basis of diabetic retinopathy.[79,80]

Kumari Suchitra et al.

Figure 5. Biochemical basis and emerging molecular targets

- A number of growth factors have been associated with the development of Diabetic Retinopathy.[81,82] Basic fibroblast growth factor (b FGF).[83] Insulin like growth factor 1(IGF-1).[84] Angiopoitin 1 and 2[85,86], stromal derived factor 1 87 ,Epidermal growth factor(EGF)[88], Transforming growth factor β 2(TGF- β 2)[89], Platelet derived growth factor[90] and Erythropoitin91 have been found associated with DR.

- Anti VEGF agents are recently developed as a treatment modality in DR. Pegaptenib, Ranibizumab, Bevacizumab are some of the current anti VEGF agents.[92-95] Recent advances suggest cautious use of anti VEGF agents on long term basis to treat DR due to the fact that VEGF has a role as retinal neuron survival factor and its inhibition may lead to destruction of cells i.e. photoreceptors, muller glia that are involved in visual function.[96]

- Many studies highlighted the importance of subclinical inflammation in the development of DR.[97-99] Hyperglycaemia , hypertension, oxidative stress ,Advanced Glycation End products all contribute to inflammation and inflammatory response in tern regulates these pathways via cytokines, VEGF signalling, adhesion molecules, Enhanced RAGE expression, NFkB signalling. Leucostasis is another hallmark in the pathogenesis of DR as it causes capillary occlusion, ROS mediated cell death that enhance inflammatory response locally in retinal tissues.[100] Therefore subclinical inflammation in the retina leads to increased intra ocular pressure, formation of new, weak vessels and their increased permeability due to VEGF that cause retinal haemorrhage. Activation of microglia and immune cells is also revealed by many researchers.[101] This fact has been supported by the use of Minocyclin, an antibiotic and anti-inflammatory agent that block the activation of Microglia and prevent DR.[102] The use of intravitreal Triamcinolone acetonide and non-steroidal anti-inflammatory drugs i.e. Nepafenac has been reported to reduce VEGF expression, normalize vascular permeability and reduce apoptosis , leucostasis that improve visual acuity.[103,104] There is also great deal of interest in intraocular implants that deliver anti-inflammatory steroids.[105,106]

- A significant relationship between VEGF and IL-6 was reported by Funatsu et al. Aqueous levels of these two

parameters were correlated with the severity of fundus findings.[107] Recently VEGF & IL-6 relationship & their levels in vitreous fluid has been documented[108,109] thus pointing towards the usefulness of their measurement as an analytical marker of pathogenesis of DR and to predict the progression of retinal diseases.

- Matrix Metalloproteinases (MMP) 2.9 and their tissue inhibitors (TIMP) were found elevated in vitreous of diabetic patients and were correlated with severity of retinopathy.[110, 111] MMP activity represent the " final common pathway" in retinal neovascularisation from whatever cause and therapeutic inhibition at this level may be more effective then targeting individual pathway.

- Endothelin-1 (ET-1) is a peptide produced by the endothelial cells that induces vasoconstriction. Studies reported that hypoxia induces ET-1 gene expression in endothelial cells.[112] A position association between ET-1 expression and PKC activation in early diabetes reflected the fact that PKC inhibitors could be able to reverse the upregulation of ET-1.[113] Therapeutic effect of long-term selective blockade of endothelin A (ETA) receptor has been recently evaluated in a genetic mouse model of non obese type-1 diabetes.[114] Such studies suggest a new strategy for preventing development of retinopathy in diabetes.

Fenofibrate (Peroxisome proliferator activated receptor PPAR-α agonist) is used to treat high triglycerides and low HDL or as adjunct to statin therapy. It regulates the expression of many genes that work against lipids, inflammation, angiogenesis, and cell apoptosis. The ACCORD Eye Study group involved a subset of 2,856 participants reported that the rates of progression of diabetic retinopathy were significantly reduced in the intensive glycemic control group and in the fenofibrate group.[115]

CONCLUSION

The pathogenesis of DR is very complex and many biochemical mechanisms have been proposed which are interactive and interdependent. This review provides better understanding of complex biochemical mechanisms and treatment modalities of recent Interest. At proliferative phase of retinopathy therapeutic interventions are effective but in advanced stage hypoxia induced VEGF production leads to disease progression. Overexpression of growth factors i.e. VEGF, IGF-1, stromal derived GF-1, angiopoetin- 1 & 2, fibroblast Growth Factor act in synergy in mediating process of angiogenesis and endothelial are proliferation. As there is a complex interplay between the biochemical pathways, understanding the molecular basis of these pathways in greater details will help in exploring newer pharmacological agents targeted to block different pathways that could provide a better insight in preventing the disease progression in Diabetic Retinopathy.

CONFLICT OF INTEREST

Nil.

REFERENCES

1) C Giusti, P Gargiulo. Advances in biochemical mechanisms of Diabetic Retinopathy. European review for Medical and Pharmacological Sciences 2007; 11: 155-163.

2) Q. D. Nguyen, S.M. Shah, A. A. Khwaja .Two-year outcomes of the ranibizumab for edema of the macula in diabetes (READ-2) study. Ophthalmology 2010;117 : 2146–2151

3) Y. Zheng, M. He, and N. Congdon. The worldwide epidemic of diabetic retinopathy. Indian Journal of Ophthalmology 2012; 60: 428–431.

4) Heintz E, Wirhn AB, PeeBo BB, Rosenqvist O, Levin LA. Prevalence and health care cost of Diabetic retinopathy: a population based register study in Sweden. Diabetologia 2010; 53:2147-2154.

5) Klein R, Knudtson MD, Lee KE, Gangnon R, Klein BE. The Wisconsin epidemiologic study of diabetic retinopathy: XXII the twenty five year progression of retinopathy in persons with type-1 diabetes. Ophthalmology. 2008;115:1859-1868.

6) D. N. Sang and P. A. D'Amore, Is blockade of vascular endothelial growth factor beneficial for all types of diabetic retinopathy? Diabetologia 2008; 51: 1570–1573.

7) I. Cilensek, S. Mankoc, M. G. Petrovic, and D. Petroviˇc.The4a/4a genotype of the VNTR polymorphism for endothelial nitric oxide synthase (eNOS) gene predicts risk for proliferative diabetic retinopathy in Slovenian patients (Caucasians) with type 2 diabetes mellitus. Molecular Biology Reports 2012; 39: 7061–7067.

8) The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin dependent diabetes mellitus. The New England Journal of Medicine 1993; 329: 977–986.

9) Q. Mohamed, M. C. Gillies, and T. Y. Wong. Management of diabetic retinopathy: a systematic review. Journal of the American Medical Association 2007; 298: 902–916.

10) D. S. Fong, A. Girach, and A. Boney. Visual side effects of successful scatter laser photocoagulation surgery for proliferative diabetic retinopathy: a literature review. Retina 2007; 27:816–824.

11) N. H. White, P. A. Cleary, W. Dahms .Beneficial effects of intensive therapy of diabetes during adolescence: Outcomes after the conclusion of the Diabetes Control and Complications Trial (DCCT).The Journal of Paediatrics 2001; 139: 804–812.

12) D. R. Matthews, I. M. Stratton, S. J. Aldington, R. R. Holman, and E. M. Kohner. Risks of progression of retinopathy and vision loss related to tight blood pressure control in type 2 diabetes mellitus: UKPDS 69.Archives of Ophthalmology 2004;122 :1631–1640.

13) Aiello LP. Perspectives on diabetic retinopathy. American journal of Ophthalmology 2003; 136: 122-135.

14) Fong D S, A Siellolp, Ferris FL 3rd, Klein R. Reviews-Diabetic retinopathy. Diabetes Care2004;27: 2540-2553.

15) K. H. Gabba. The sorbitol pathway and the complications of diabetes. The New England Journal of Medicine 1973;288 :831-836.

16) B. S. Szwergold, F. Kappler, and T. R. Brown .Identification of fructose 3-phosphate in the lens of diabetic rats. Science 1990;247: 451–454.

17) P. A. Barnett, R. G. Gonzalez, L. T. Chylack, and H. M. Cheng. The effect of oxidation on sorbitol pathway kinetics.Diabetes1986; 35: 426–432.

18) B. Lassègue and R. E. Clempus. Vascular NAD(P)H oxidases: specific features, expression, and regulation. American Journal of Physiology 2003; 285: R277–R297.

19) K. H. Gabbay. Purification and immunological identification of bovine retinal aldose reductase. Israel Journal of Medical Sciences 1972; 8:1626–1629.

20) S. F. Travis, A. D. Morrison, R. S. Clements Jr., A. I. Winegrad, and F. A. Oski. The role of the polyol pathway in methaemoglobin reduction in human red cells. British Journal of Haematology 1974;27:597–605.

21) Dagher z, Park ys, Asnaghi v, Hoehn t, Gerhardinger c, Lorenzi M. Studies of rat and human retina predict a role for the polyol pathway in humandiabetic retinopathy. Diabetes 2004; 53:2404-2411.

22) Oyama T, Miyasita Y, Watanabe H, Shirai K. The roleofpolyol pathway in high glucose-induced endothelial cell damages. Diabetes Res ClinPract2006 (in press).

23) Wautier MP, Massin P, Guillausseau PJ, Huijberts M, Levy B, Boulanger E et al. N(carboxymethyl)lysine as a biomarker for microvascular complications in type 2 diabetic patients. Diabetes Metabolism2003; 29: 44-52.

24) Z. Dagher, Y. S. Park, V. Asnaghi, T. Hoehn, C. Gerhardinger, and M. Lorenzi. Studies of rat and human retinas predict a rolefor the polyol pathway in human diabetic retinopathy. Diabetes 2004;53: 2404–2411.

25) C. Hennekens. A randomized trial of sorbinil, an aldose reductase inhibitor, in diabetic retinopathy. Archives of Ophthalmology 1990; 108:1234–1244.

26) I. G. Obrosova, P. Pacher, C. Szab´O.Aldose reductase inhibition counteracts oxidative-nitrosative stress and poly(ADP ribose)polymerase activation in tissue sites for diabetes complications. Diabetes 2005; 54:234–242.

27) V. R. Drel, P. Pacher, T. K. Ali .Aldose reductase inhibitor fidarestat counteracts diabetes-associated cataract formation, retinal oxidative-nitrosative stress, glial activation, and apoptosis. International Journal of Molecular Medicine 2008; 21: 667–676.

28) I. G. Obrosova, Y. Maksimchyk, P. Pacher .Evaluation of the aldose reductase inhibitor fidarestat on ischemia reperfusion injury in rat retina. International Journal of Molecular Medicine 2010;26: 135–142.

29) T. Hattori, A. Matsubara, K. Taniguchi, and Y. Ogura. Aldose reductase inhibitor fidarestat attenuates leukocyte-endothelial interactions in experimental diabetic rat retina in vivo. Current Eye Research 2010; 35:146–154.

30) A. A. F. Sima, V. Bril, V. Nathaniel .Regeneration and repair of myelinated fibers in sural-nerve biopsy specimens from patients with diabetic neuropathy treated with sorbinil. The New England Journal of Medicine 1988;319:548–555.

31) D. A. Greene, J. Arrezo, and M. Brown. Dose-related effects of the aldose reductase inhibitor Zenarestat on nerve sorbitol levels, nerve conduction velocity and nerve fibre density inhuman diabetic neuropathy. Diabetes 1996;45 :574-581.

32) D. A. Greene, J. C. Arezzo, and M. B. Brown Effect of aldose reductase inhibition on nerve conduction and morphometry indiabetic neuropathy. Neurology 1999; 53: 580–591.

33) H. Zong, M. Ward, and A. W. Stitt. AGEs, RAGE, and diabetic retinopathy. Current Diabetes Reports 2011;11:244–252.

34) Wautier MP, Boulanger E, Guillausseau P Jj, Massin P, Wautierjl. AGES, macrophage colony stimulating factor and vascular adhesion molecule blood levels are increased in patients with diabetic microangiopathy. Thromb Haemost. 2004; 91: 879-885.

35) A. W. Stitt. Advanced glycation: an important pathological event in diabetic and age related ocular disease. British Journal of Ophthalmology 2001; 85:746–753.

36) Z. Mokini, M. L. Marcovecchio, and F. Chiarelli. Molecular pathology of oxidative stress in diabetic angiopathy: role of mitochondrial and cellular pathways. Diabetes Research and Clinical Practice 2010; 87: 313–321.

37) R. A. Kowluru, V.Kowluru, Y. Xiong, and Y. HO. Over expression of mitochondrial superoxide dismutase in mice protects the retina from diabetes-induced oxidative stress. Free Radical Biology and Medicine 2006; 41: 1191–1196.

38) R. A. Kowluru, R. L. Engerman, G. L. Case, and T. S. Kern. Retinal glutamate in diabetes and effect of antioxidants. Neurochemistry International 2001;38:385–390.

39) P. Chan, M. Kanwar, and R. A. Kowluru. Resistance of retinal inflammatory mediators to suppress after reinstitution of good glycemic control: novel mechanism for metabolic memory. Journal of Diabetes and its Complications 2010;24: 55–63.

40) H. M. Lander, J. M. Tauras, J. S. Ogiste, O. Hori, R. A. Mossand A. M. Schmidt. Activation of the receptor for advanced glycation End products triggers a p21ras-dependent mitogen activated protein kinase pathway regulated by oxidant stress. The Journal of Biological Chemistry 1997;272: 17810–17814.

41) S. Sugiyama, T. Miyata, Y. Ueda .Plasma levels of pentosidine in diabetic patients: an advanced glycation end product. Journal of the American Society of Nephrology. 1998; 9: 1681–1688.

42) W. Wang, M. Matsukura, I. Fujii. Inhibition of high glucose-induced VEGF and ICAM-1 expression in human retinal pigment epithelium cells by targeting ILK with small interference RNA. Molecular Biology Reports 2012; 39: 613–620.

43) M. P. Wautier, P. Massin, P. J. Guillausseau. N (carboxymethyl) lysine as a biomarker for microvascular complications in type diabetic patients. Diabetes and Metabolism 2003; 29: 44–52.

44) A. Stitt, T. A. Gardiner, N. L. Anderson. The AGE inhibitor pyridoxamine inhibits development of retinopathy in experimental diabetes. Diabetes 2002; 51: 2826–2832.

45) S. Yamagishi, H. Fujimori, H. Yonekura, Y. Yamamoto, and H. Yamamoto. Advanced glycation end products inhibit prostacyclin production and induce plasminogen activator inhibitor-1in human microvascular endothelial cells. Diabetologia 1998; 41: 1435–1441.

46) T. Okamoto, S. Yamagishi, Y. Inagaki .Angiogenesis induced by advanced glycation end products and its prevention by cerivastatin. The FASEB Journal 2002; 16: 1928–1930.

47) H. P. Hammes, S. Martin, K. Federlin, K. Geisen, and M. Brownlee. Aminoguanidine treatment inhibits the development of experimental diabetic retinopathy. Proceedings of the National Academy of Sciences of the United States of America 1991; 88: 11555–11558.

48) H. Zong, M. Ward, and A. W. Stitt. AGEs, RAGE, and diabetic retinopathy. Current Diabetes Reports 2011;11: 244–252.

49) R. Singh, A. Barden, T. Mori, and L. Beilin. Advanced glycation end-products: a review. Diabetologia 2001; 44: 129–146.

50) S. Sheikpranbabu, R. Haribalaganesh, and S. Gurunathan. Pigment epithelium-derived factor inhibits advanced glycation end-products-induced cytotoxicity in retinal pericytes. Diabetes& Metabolism 2011;37: 505–511.

51) S. Yamagishi, T. Matsui, K. Nakamura, M. Takeuchi, and T. Imaizumi. Pigment epithelium-derived factor (PEDF) prevents diabetes- or advanced glycation end products (AGE)-elicited retinal leukostasis. Microvascular Research 2006; 72: 86–90.

52) K. Park, K. Lee, B. Zhang. Identification of a novel inhibitor of the canonical Wnt pathway. Molecular and Cellular Biology 2011;31: 3038–3051.

53) Yokoi M, Yamagishi SI, Takeuchi M, Ohgami K, Okamoto T, Saito W et al. Elevations of AGE and vascular endothelial growth factor with decreased total antioxidant status in the vitreous fluid of diabetic patients with retinopathy. Br J Ophthalmol 2005; 89:673-675.

54) Amano S, Yamagishi S, Inagaki Y, Nakamura K, Takeuchi M, Inoue H et al. Pigment epithelium-derived factor inhibits oxidative stress-induced apoptosis and dysfunction of cultured retinal pericytes. Microvasc Res 2005; 69: 45-55.

55) D. Armstrong, T. Ueda, T. Ueda. Lipid hydroperoxide stimulates retinal neovascularization in rabbit retina through expression of tumor necrosis factor-α, vascular endothelial growth factor and platelet-derived growth factor. Angiogenesis1998;2: 93–104.

56) R. A. Kowluru. Effect of reinstitution of good glycemic controlon retinal oxidative stress and nitrative stress in diabetic rats. Diabetes 2003; 52: 818–823.

57) K. Haskins, B. Bradley, K. Powers. Oxidative stress in type1 diabetes. Annals of the New York Academy of Sciences 2003;1005:43–54.

58) D. W. Laight, M. J. Carrier, and E. E. Anggard. Antioxidants, diabetes and endothelial dysfunction. Cardiovascular Research 2000; 47:457–464.

59) L. Packer, E. H.Witt, and H. J. Tritschler. Alpha-lipoic acid as abiological antioxidant. Free Radical Biology and Medicine1995;19 : 227–250.

60) R. A. Kowluru and S. Odenbach. Effect of long-term administration of α-lipoic acid on retinal capillary cell death and the development of retinopathy in diabetic rats. Diabetes 2004; 53: 3233–3238.

61) S. Bursell, A. C. Clermont, L. P. Aiello .High-dose vitamin E supplementation normalizes retinal blood flow and creatinine clearance in patients with type 1 diabetes. Diabetes Care 1999; 22:1245–1251.

62) G. T. Mustata, M. Rosca, K. M. Biemel. Paradoxical effects of green tea (Camellia sinensis) and antioxidant vitamins indiabetic rats: improved retinopathy and renal mitochondrial defects but deterioration of collagen matrix glycoxidation and cross-linking. Diabetes 2005; 54:517–526.

63) R. A. Kowluru, Q. Zhong, J. M. Santos, M. Thandampallayam, D. Putt, and D. L. Gierhart. Beneficial effects of the nutritional supplements on the development of diabetic retinopathy. Nutrition & Metabolism 2014; 11:586-589.

64) D. Koya and G. L. King. Protein kinase C activation and the development of diabetic complications. Diabetes 1998; 47: 859–866.

65) F. Giacco and M. Brownlee. Oxidative stress and diabetic complications. Circulation Research 2010; 107: 1058–1070.

66) Q. J. Wang. PKD at the crossroads of DAG and PKC signalling. Trends in Pharmacological Sciences 2006; 27: 317–323.

67) L. P. Aiello, A. Clermont, V. Arora, M. D. Davis, M. J. Sheetz, and S. E. Bursell. Inhibition of PKC β by oral administration of ruboxistaurin is well tolerated and ameliorates diabetes induced retinal hemodynamic abnormalities in patients.

Investigative Ophthalmology and Visual Science 2006; 47: 86–92.

68) L. P. Aiello, S. E. Bursell, A. Clermont. Vascular endothelial growth factor-induced retinal permeability is mediated byprotein kinase C in vivo and suppressed by an orally effectiveβ-isoform-selective inhibitor. Diabetes 1997; 46:1473–1480.

69) D. Koya and G. L. King. Protein kinase C activation and the development of diabetic complications. Diabetes 1998; 47: 859–866.

70) P. Geraldes and G. L. King. Activation of protein kinase C isoforms and its impact on diabetic complications. Circulation Research 2010; 106: 1319–1331.

71) C. Rosse, M. Linch, S. Kermorgant, A. J. M. Cameron, K. Boeckeler, and P. J. Parker. PKC and the control of localized signal dynamics. Nature Reviews Molecular Cell Biology 2010; 11: 103–112.

72) D. Koya and G. L. King. Protein kinase C activation and the development of diabetic complications. Diabetes 1998; 47: 859–866.

73) D. Liao, B. Monia, N. Dean, and B. C. Berk. Protein kinase C-mediates angiotensin II activation of ERK1/2 in vascular smooth muscle cells. Journal of Biological Chemistry 1997; 272: 6146–6150.

74) H. Ishii, M. R. Jirousek, D. Koya .Amelioration of vascular dysfunctions in diabetic rats by an oral PKC β inhibitor. Science 1996; 272: 728–731.

75) D. Koya, M. R. Jirousek, Y. Lin, H. Ishii, K. Kuboki, and G. L. King. Characterization of protein kinase C β isoform activation on the gene expression of transforming growth factor-β, extracellular matrix components, and prostanoids in the glomeruli of diabetic rats. Journal of Clinical Investigation 1997;100: 115–126.

76) P. Xia, L. P. Aiello, H. Ishii. Characterization of vascular endothelial growth factor's effect on the activation of protein kinase C, its isoforms, and endothelial cell growth. The Journal of Clinical Investigation 1996; 98: 2018–2026.

77) K. R. Tuttle, G. L. Bakris, R. D. Toto, J. B. McGill, K. Hu, and P.W. Anderson. The effect of ruboxistaurin on nephropathy in type 2 diabetes. Diabetes Care 2005; 28 : 2686–2690.

78) Giusti C, Schiaffini R, Brufani C, Pantaleo A, Vingol OEM, Gargiulo P. Coagulation pathways and diabetic retinopathy: abnormal modulation in a selected group of insulin-dependent diabetic patients.Br J Ophthalmol 2000; 84: 591-595.

79) GIusti C. Retinopathy in juvenile diabetes: a 10-year (1990-2000) review. Pediatr Diabetes 2001;2: 83-93.

80) Giusti C. Are phospholipid-binding antibodies implicated in the pathogenesis of diabetic microangiopathy? Med Hypotheses 2004; 63: 235-238.

81) M. B. Grant, R. N. Mames, C. Fitzgerald. The efficacy ofoctreotide in the therapy of severe nonproliferative and early proliferative diabetic retinopathy: a randomized controlled study," Diabetes Care 2000; 23: 504–509.

82) B. R. Zimmerman and G. D. Molnar. Prolonged follow up indiabetic retinopathy treated by sectioning the pituitary stalk. Mayo Clinic Proceedings 1977; 52: 233–237.

83) A. Hueber, P. Wiedemann, P. Esser, and K. Heimann. Basic Fibroblast growth factor mRNA, bFgF peptide and FGF receptorin epiretinal membranes of intraocular proliferative disorders(PVR and PDR). International Ophthalmology 1996 ; 20 : 345–350.

84) V. Haurigot, P. Villacampa, A. Ribera .Increased intraocular insulin-like growth factor-I triggers blood-retinal barrier breakdown. e Journal of Biological Chemistry 2009; 284 : 22961–22969.

85) J. I. Patel, P. G. Hykin, Z. J. Gregor, M. Boulton, and I. A. Cree. Angiopoietin concentrations in diabetic retinopathy. British Journal of Ophthalmology 2005; 89: 480–483.

86) S. Rangasamy, R. Srinivasan, J. Maestas, P. G. McGuire, and A. Das. A potential role for angiopoietin 2 in the regulation ofthe blood-retinal barrier in diabetic retinopathy. Investigative Ophthalmology and Visual Science 2011; 52: 3784–3791.

87) H. L. Brooks Jr., S. Caballero, C. K. Newell. Vitreous levels of vascular endothelial growth factor and stromal-derived factor1 in patients with diabetic retinopathy and cystoid macular edema before and after intraocular injection of triamcinolone. Archives of Ophthalmology 2004;122: 1801–1807.

88) A. Lev-Ran, D. L. Hwang, J. D. Miller, and Z. Josefs berg. Excretion of epidermal growth factor (EGF) in diabetes. Clinica Chimica Acta 1990; 192: 201–206.

89) S. H. Min, T. I. Lee, Y. S. Chung, and H. K. Kim. Transforming growth factor-α levels in human aqueous humor of glaucomatous, diabetic and uveitic eyes. Korean Journal of Ophthalmology. 2006; 20: 162–165.

90) A. Praidou, I. Klangas, E. Papakonstantinou. Vitreousand serum levels of platelet-derived growth factor and their correlation in patients with proliferative diabetic retinopathy. Current Eye Research 2009; 34: 152–161.

91) K. U. Eckardt. Erythropoietin and microvascular diabetic complications. Nephrology Dialysis Transplantation 2009; 24: 388–390.

92) A. P. Adamis, M. Altaweel, N. M. Bressler. Changes in retinal neovascularization after pegaptanib (Macugen) therapy in diabetic individuals," Ophthalmology 2006; 113: 23–28.

93) R. L. Avery, J. Pearlman, D. J. Pieramici. Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy. Ophthalmology 2006; 113 : 1695.e6–1705.e6.

94) D. W. Chun, J. S. Heier, T. M. Topping, J. S. Duker, and J.M. Bankert. A pilot study of multiple intravitreal injections of ranibizumab in patients with center-involving clinically significant diabetic macular edema. Ophthalmology 2006; 113: 1706–1712.

95) Q. D. Nguyen, S. Tatlipinar, S. M. Shah .Vascular endothelial growth factor is a critical stimulus for diabetic macular edema. American Journal of Ophthalmology 2006; 142: 961.e4–969.e4.

96) A. M. Joussen, V. Poulaki, W. Qin. Retinal vascular endothelial growth factor induces intercellular adhesionmolecule-1 and endothelial nitric oxide synthase expression and initiates early diabetic retinal leukocyte adhesion in vivo. American Journal of Pathology 2002; 160 : 501–509.

97) M. V. van Hecke, J. M. Dekker, G. Nijpels. Inflammationand endothelial dysfunction are associated with retinopathy: the Hoorn study. Diabetologia 2005; 48: 1300–1306.

98) A. M. W. Spijkerman, M. A. Gall, L. Tarnow .Endothelial dysfunction and low-grade inflammation and the progression of retinopathy in type 2 diabetes. Diabetic Medicine 2007; 24: 969–976.

99) B. E. K. Klein, M. D. Knudtson, M. Y. Tsai, and R. Klein. The relation of markers of inflammation and endothelial dysfunction to the prevalence and progression of diabetic retinopathy: Wisconsin epidemiologic study of diabetic retinopathy. Archives of Ophthalmology 2009; 127: 1175–1182.

100) R. Chibber, B. M. Ben-Mahmud, G. E. Mann, J. J. Zhang, and E. M. Kohner,. Protein kinase C 2-dependent phosphorylation of core 2 GlcNAc-T promotes leukocyte-endothelial cell adhesion: a mechanism underlying capillary occlusion in diabetic retinopathy. Diabetes 2003; 52: 1519–1527.

101) T. Langmann. Microglia activation in retinal degeneration. Journal of Leukocyte Biology 2007; 81:1345–1351.

102) P. P. Sfikakis, V. Grigoropoulos, I. Emzetzoglou. Nfliximab for diabetic macular edema refractory to laser photo coagulation: a randomized, double-blind, placebo-controlled, crossover, 32-week study. Diabetes Care 2010; 33: 1523–1528.

103) M. C. Gillies, F. K. P. Sutter, J. M. Simpson, J. Larsson, H. Ali, and M. Zhu. Intravitreal triamcinolone for refractory diabetic macular edema. Two-year results of a double-masked, placebo controlled, randomized clinical trial. Ophthalmology 2006; 113: 1533–1538.

104) B. D. Kuppermann, M. S. Blumenkranz, J. A. Haller. Randomized controlled study of an intravitreous dexamethasone drug delivery system in patients with persistent macular edema. Archives of Ophthalmology 2007; 125: 309–317.

105) J. A. Montero and J. M. Ruiz-Moreno. Intravitreal inserts of steroids to treat diabetic macular edema. Current Diabetes Reviews 2009; 5: 26–32.

106) M. Ottiger, M. A. Thiel, U. Feige, P. Lichtlen, and D. M. Urech. Efficient intraocular penetration of topical anti-TNF-α single chainantibody (ESBA105) to anterior and posterior segment without penetration enhancer. Investigative Ophthalmologyand Visual Science2009; 50: 779–786.

107) Funatsu H, Yamashita H, Shimizu E, Kojima R, Hori S. Relationship between vascular endothelial growth factor and interleukin-6 in diabetic retinopathy. Retina 2001; 21: 469-477.

108) Funatsu H, Yamashita H, Noma H, Mimura T, Nakamura S, Sakata K et al. Aqueous humor levels of cytokines are related to vitreous levels and progression of diabetic retinopathy in diabetic patients. Graefes Arch Clin Exp Ophthalmol 2005; 243: 3-8.

109) Maberley D, Cui JZ, Matsubara JA. Vitreous leptin levels in retinal disease. Eye 2006; 20: 801-804.

110) Ishizaki E, TakaiS, Ueki M, Maeno T, Maruichi M, Sugiyama T et al . Correlation between angiotensin-converting enzyme, vascular endothelial growth factor, and matrix metalloproteinase-9 in the vitreous of eyes with diabetic retinopathy. Am J Ophthalmol 2006; 141: 129-134.

111) Jacqueminet S, Ben Abdesselam O, Chapman MJ,Nicolay N, Foglietti MJ, Grimaldi A, Beaudeux JL. Elevated circulating levels of matrix metalloproteinase-9 in type 1 diabetic patients with and without retinopathy. Clin Chim Acta 2006 ; 367;103-107.

112) Roldan-PAllares M, Rollin R, Mediero A, Martinez Montero JC, Fernandez-cruz A, Bravo-llata C, Fernandez et al . Immunoreactive ET-1 in the vitreous humor and epiretinal membranes of patients with proliferative vitreo retinopathy. Mol Vis 2005; 11: 461-471.

113) Zhu Q, XU X, XIA X, GU Q, HO PC. Role of protein kinase C on the alteration of retinal endothelin-1in streptozotocin-induced diabetic rats. Exp EyeRes 2005; 81: 200-206.

114) Shaw SG, Boden JP, Biecker E, Reichen J,Rothen B. Endothelin antagonism prevents diabetic retinopathy in NOD mice: a potential role of the angiogenic factor adrenomedullin. Exp Bio lMed 2006; 231; 1101-1105.

115) A. Keech, P. Mitchell, P. Summanen. "Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial". The Lancet 2007: 370: 1687–1697.